© Gerd Altmann/pixabay.com

Using data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease.

Aspergillus spores could become dangerous for people with a weakened immune system. © CDC

UK-Austrian fungal infection specialist F2G Ltd has secured a €50.8m (US $60.8m) financing from new and existing investors.

© Nikolay Frolochkin/Pixabay.com

Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.

Picture: MC Services AG

COVID-19 has put life science research companies into the limelight. An Interview with Raimund Gabriel, founder and managing director MC Services AG, on the role of corporate communications in the corona crisis.

Barbara McManus as the new managing director of Nottingham-based Contract Research Organisation (CRO) HistologiX.

Dr Norbert Rau redesigned the 25-year-old euroPLX partnering concept. Picture: RauCon GmbH & Co. KG

An ongoing crisis and evolving new working habits of industry executives call for an entirely new and up-to-date partnering format. Workarounds such as moving a partnering event’s scheduled one-on-one meetings online is neither imaginative nor does it meet the requirements of flexibility and effectiveness. The format presented here sounds the bell for a new era of pharma partnering.

© BioNTech SE 2020, all rights reserved

BioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.

Picture: ©Evotec

Evotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.

PCA can detect SARS-CoV-2 within 15 minutes. Picture: GNA Biosolutions GmbH

Rapid tests have received a lot of attention during the Coronavirus pandemic, but as the number of tests available has increased, so has the confusion around the different types and what they can deliver. What if there were laboratory quality tests that could produce a result in just a few minutes?

© Arek Socham/Pixabay.com

The European Commission has reserved 300 million doses from Sanofi SA’/GSK plc’s adjuvanted recombinant COVID-19 vaccine.